Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dxd (OQM5SD32BQ) is a potent inhibitor of DNA topoisomerase I with an IC50 of 0.31 μM. It is used as a conjugated drug of HER2-targeting ADC.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 68.00 | |
10 mg | In stock | $ 97.00 | |
25 mg | In stock | $ 159.00 | |
50 mg | In stock | $ 233.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 74.00 |
Description | Dxd (OQM5SD32BQ) is a potent inhibitor of DNA topoisomerase I with an IC50 of 0.31 μM. It is used as a conjugated drug of HER2-targeting ADC. |
Targets&IC50 | Topo I:0.31 μM |
In vitro | Dxd shows obviously suppression on the HER2-positive KPL-4, NCI-N87, and SK-BR-3 cell lines with IC50s of 26.8, 25.4, and 6.7 ng/mL respectively, but with no such inhibition on MDA-MB-468 (IC50, >10,000 ng/mL)[1]. |
In vivo | Dxd is cytotoxic to human cancer cell lines of KPL-4, NCI-N87, SK-BR-3, and MDA-MB-468 with IC50s of 1.43 nM-4.07 nM. In HER2 low-expressing ST565 and ST313 models has HER2 IHC 1+/FISH-negative expression[1]. |
Synonyms | Exatecan derivative for ADC, OQM5SD32BQ, UNII-OQM5SD32BQ |
Molecular Weight | 493.48 |
Formula | C26H24FN3O6 |
CAS No. | 1599440-33-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: insoluble
DMSO: 50 mg/mL (101.32 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Dxd 1599440-33-1 DNA Damage/DNA Repair Topoisomerase Inhibitor ADC Exatecan derivative for ADC ADC Cytotoxin inhibit OQM5SD32BQ UNII-OQM5SD32BQ HER2-targeting ADC Payload inhibitor